The MSCI ACWI IMI Immuno-oncology Index aims to represent the performance of a set of companies that are associated with research, development, and commercialization of products for cancer immunotherapy, also known as Immuno-oncology.

The LibertyQ Global Equity Index is based on the MSCI ACWI Index, its parent index, which includes large and mid-cap stocks across Developed and Emerging Market countries.

MSCI ESG Metrics is designed to deliver a broad set of standardized ESG data and simple metrics that are comparable across a broad universe of 8,500 companies (the MSCI ACWI Investable Market Index (IMI)).

Global benchmarks can understate the economic importance of emerging markets but looking at the evolution of the MSCI Emerging Markets Index and its weight in the ACWI, is a testament to the important role EM plays in global asset allocation.

The Invesco Revenue Weighted Global ESG Index is designed to represent the performance of companies that have historically demonstrated relatively higher risk adjusted performance and Industry Adjusted ESG Scores within the MSCI ACWI universe.

The composition of the global stock market has changed substantially over the last 10 years. But which regions have gained or lost market share by sector? This infographic shows the regional breakdown of MSCI ACWI IMI for each sector in 2011 and 2021.

The MSCI Emerging Markets Index’s weight in the MSCI ACWI Index rose from 0.9% in January 1987 to 12% in June 2020. EM continued to be characterized by its exposure to unique growth opportunities, significant dispersion of country performances, as well as the historical factor/ESG premium.

The number of women on corporate boards increases yearly, but the growth rate slowed in 2020 following a moderate uptick in 2019. MSCI ESG Research observed a 0.6% growth rate among MSCI ACWI Index companies in 2020, and outlined three projection scenarios for the decades ahead.

Methodology

Indexes

Methodology

Indexes